Loading...
XMAD
FAE
Market cap1.26bUSD
Apr 07, Last price  
3.72EUR
1D
-4.37%
1Q
6.29%
Jan 2017
10.71%
Name

Faes Farma SA

Chart & Performance

D1W1MN
P/E
10.40
P/S
2.35
EPS
0.36
Div Yield, %
4.17%
Shrs. gr., 5y
2.51%
Rev. gr., 5y
6.67%
Revenues
494m
+9.42%
166,449,000185,187,000185,940,000194,180,000131,406,000202,507,000190,224,000176,109,000180,394,000191,742,000204,724,000228,635,000274,576,000324,312,000357,398,000380,240,000398,557,000438,754,000451,168,000493,647,000
Net income
111m
+21.17%
23,273,00022,772,00022,149,00019,615,00018,161,00020,002,00014,181,00019,518,00022,605,00025,334,00030,361,00036,591,00042,221,00051,592,00063,962,00072,549,00082,390,00089,496,00091,902,000111,360,000
CFO
115m
+14.36%
19,930,00013,044,00034,308,00016,946,00015,238,00019,975,00023,872,00031,647,00032,259,00040,912,00049,625,00041,727,00059,336,00067,585,00078,489,00079,645,000106,788,000100,969,000115,468,000
Dividend
Jul 04, 20240.116 EUR/sh
Earnings
Jul 28, 2025

Profile

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.
IPO date
Mar 25, 1994
Employees
1,764
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
493,647
9.42%
451,168
2.83%
438,754
10.09%
Cost of revenue
167,109
216,621
212,926
Unusual Expense (Income)
NOPBT
326,538
234,547
225,828
NOPBT Margin
66.15%
51.99%
51.47%
Operating Taxes
(3,538)
11,159
11,919
Tax Rate
4.76%
5.28%
NOPAT
330,076
223,388
213,909
Net income
111,360
21.17%
91,902
2.69%
89,496
8.62%
Dividends
(48,244)
(14,607)
(18,147)
Dividend yield
4.48%
1.49%
1.69%
Proceeds from repurchase of equity
(17,686)
BB yield
1.80%
Debt
Debt current
1,988
19,523
28,285
Long-term debt
10,979
10,565
Deferred revenue
1,114
4,786
Other long-term liabilities
6,322
4,570
35
Net debt
(62,412)
(4,481)
(50,382)
Cash flow
Cash from operating activities
115,468
100,969
106,788
CAPEX
(39,520)
(102,190)
(80,948)
Cash from investing activities
(34,180)
(97,356)
(92,172)
Cash from financing activities
(51,713)
(35,377)
(18,459)
FCF
324,616
144,848
140,788
Balance
Cash
72,144
47,751
84,100
Long term investments
(7,744)
(12,768)
5,132
Excess cash
39,718
12,425
67,294
Stockholders' equity
241,413
673,561
617,405
Invested Capital
696,324
679,390
570,184
ROIC
47.99%
35.75%
39.75%
ROCE
43.44%
33.09%
34.36%
EV
Common stock shares outstanding
309,333
310,729
305,920
Price
3.48
10.13%
3.16
-9.97%
3.51
0.92%
Market cap
1,076,480
9.63%
981,905
-8.56%
1,073,779
1.28%
EV
1,014,816
978,418
1,024,600
EBITDA
346,856
253,945
245,099
EV/EBITDA
2.93
3.85
4.18
Interest
433
684
263
Interest/NOPBT
0.13%
0.29%
0.12%